Tyler Baumeister
Tyler Baumeister has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Jarett Worden
College of Pharmacy & Health Sciences, Belmont University, Nashville, TN 37212, USA
2 shared publications - Ellen F. Eaton
Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA
1 shared publication - Nancy Henin
Williamson Medical Center, 4321 Carothers Parkway, Franklin, TN 37067
1 shared publication - Rebecca A. Stern
Vanderbilt University Medical Center
1 shared publication - Sarah Stogner
Pharmacy Student, Class of 2026, Belmont University College of Pharmacy & Health Sciences, 1900 Belmont Blvd, Nashville, TN 37212
1 shared publication
Latest Publications
- Open Access
- 9 September 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (9) , 881
Optimizing Treatment of Infective Endocarditis in Patients Who Inject Drugs
The treatment of infective endocarditis (IE) in patients who inject drugs (PWID) is complex and challenging. These patients face stigma in the healthcare system, as well as higher mortality, longer length of hospital stay, higher rates of recurrent infections, and lower likelihood of antibiotic completion. Standard treatment for IE involves several weeks of antibiotics. For PWID, these prolonged courses often mean intravenous antibiotics administered in the inpatient setting for at least 4 to 6 weeks, which increases both healthcare costs and the risk of patient-directed discharge against medical advice. Effective treatment of IE in PWID involves a combination of addiction management and appropriate antibiotic therapy. To promote rational use of healthcare resources and optimize antibiotic stewardship, novel approaches to antibiotic therapy must be utilized. This review discusses evidence supporting treatment strategies outside of the inpatient hospital setting, including outpatient parenteral antibiotic therapy (OPAT), long-acting lipoglycopeptides, and oral antibiotic therapy for the treatment of endocarditis. Optimal treatment of IE in PWID involves support from a multidisciplinary healthcare team, management of substance use disorder, and effective antibiotic therapy.
- 9 September 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (9) , 881
Open AccessOptimizing Treatment of Infective Endocarditis in Patients Who Inject Drugs
The treatment of infective endocarditis (IE) in patients who inject drugs (PWID) is complex and challenging. These patients face stigma in the healthcare system, as well as higher mortality, longer length of hospital stay, higher rates of recurrent infections, and lower likelihood of antibiotic completion. Standard treatment for IE involves several weeks of antibiotics. For PWID, these prolonged courses often mean intravenous antibiotics administered in the inpatient setting for at least 4 to 6 weeks, which increases both healthcare costs and the risk of patient-directed discharge against medical advice. Effective treatment of IE in PWID involves a combination of addiction management and appropriate antibiotic therapy. To promote rational use of healthcare resources and optimize antibiotic stewardship, novel approaches to antibiotic therapy must be utilized. This review discusses evidence supporting treatment strategies outside of the inpatient hospital setting, including outpatient parenteral antibiotic therapy (OPAT), long-acting lipoglycopeptides, and oral antibiotic therapy for the treatment of endocarditis. Optimal treatment of IE in PWID involves support from a multidisciplinary healthcare team, management of substance use disorder, and effective antibiotic therapy.
- 19 December 2025
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 66 (2) , 103009
Methemoglobinemia induced by dapsone, hydroxychloroquine, and rifampin combination for post-treatment Lyme disease syndrome: A case report
- 19 December 2025
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 66 (2) , 103009
Methemoglobinemia induced by dapsone, hydroxychloroquine, and rifampin combination for post-treatment Lyme disease syndrome: A case report